We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.
We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
CancerAppy closed 2021 with €690K total raised.
Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting..
The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.
CancerAppy raised a pre-seed round of € 50K
Enisa has granted us a loan of 100K
Cancerappy has been selected to participate in the Espacio España 4YFN 2021.
We released GeneReport 1.0
Cancerappy obtained the positive resolution of the Neotec 2020 program.
CancerAppy was one of the 24 projects selected to exhibit at the B-venture 2020 Bilbao.
AI + Drug Interaction / Personalized Medicine
CancerAppy raised a pre-seed round of € 120K
Code rewritten. Drug Interaction